INTRODUCTION
Resistance of pathogenic organisms has become a worldwide problem with serious consequence on the treatment of infectious diseases. Emergence and dissemination of β-lactam resistance in nosocomial Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumanni have pose a serious problem worldwide, especially the increasing resistance to different generations of Cephalosporins. [1] Infections due to gram-negative organisms, Pseudomonas aeruginosa being the most common, continue to be one of the leading causes of health care-acquired infections as well as morbidity and mortality in the healthcare system. [2, 3] Pseudomonas aeruginosa, a gram-negative bacterium, is found in healthcare-associated infections especially in patients who have been hospitalized more than a week and is reported in different outbreaks of infections such as pneumonia, bacteremia, urinary tract infection, and endocarditis, which are often complicated and potentially life-threatening. [4, 5] Wound infections have been the leading reservoir for the bacterium as well as burn patients. [6] Cephalosporins are used to treat a wide variety of bacterial infections caused by Pseudomonas aeruginosa not limited to respiratory tract infections, otitis media, gonorrhoea, skin infections, urinary tract infections and sexually transmitted diseases. [7] According to Oladipo et al. , [2, 3] Eyo et al., [1] and Ramalingam et al., [8] the fundamental mechanism of Pseudomonas aeruginosa resistance to cephalosporin involves the production of enzymes, extended spectrum β-lactamases (ESBLs) that aids in the bacterium resistance, that is, bacterial resistance to betalactam antibiotics is due to the enzymatic inactivation of antibiotics, that is, the production of enzyme β-lactamase which hydrolyses the β-lactam ring of the antibiotics rendering them inactive. Extensive use and misuse of antibiotics of the public alongside inappropriate practices of unskilled health workers and practitioners have led to the increasing resistance of nosocomial microorganisms.
Different generations of cephalosporin, first, second, third and fourth generations, are broad spectrum antimicrobial agents with enhanced activity against both gram-positive and gram-negative organisms. [3] They have been assured successful in the treatment of severe and multi-drug resistant infections, however, increased prevalence of nosocomial strains of Pseudomonas aeruginosa resistance to cephalosporin among clinical isolates has been reported. [9] Knowledge on the distribution of cephalosporin-resistant organisms is important for guide in empirical therapy, taking note of preventive strategies as well as control measures against the spread of resistant microorganisms. This study therefore is designed to determine the antimicrobial susceptibility pattern of selected clinical isolates to different generations of cephalosporin. 
METHODOLOGY

Bacterial isolates
A total number of one hundred (100) clinical isolates of Pseudomonas aeruginosa from different clinical sites including burns, wounds and ear were used for this study. These samples were obtained from University Teaching Hospital Ibadan.
Processing of samples
Media were prepared according to the manufacturer's instructions and sterilized at 121 0 C for 15min at 15 lb pressure. The inoculum were standardized using the MacFarland standard. [2, 3] 
Susceptibility test
The susceptibility test was conducted using the Kirby-Bauer method of sensitivity determination. [2, 3] Petri -dishes of Mueller Hinton agar were prepared according to the manufacturer's instruction. 0.1ml of Pseudomonas aeruginosa equivalent to 0.5 McFarland standard was seeded into each of the Petri-dishes containing Mueller-Hinton agar using sterile swabs. [2] These were allowed to stand for 45min to enable the inoculated organisms to pre-diffusion. [3] The antibiotics discs of Cefadroxil (30µg; Oxoid, UK), Cefotaxim (30µg; Oxoid, UK), Cefamandole (30µg; Oxoid, UK), Cefador (30µg; Oxoid, UK), Cefpodoxime (10µg; Oxoid, UK), Cefixime (5µg; Oxoid, UK) and Cefepime (30µg; Oxoid, UK) were aseptically placed on the surfaces of the sensitivity agar plates. [2, 3] These were incubated aerobically for 18-24 hours at 37ºC and the radial zone of inhibitions were taken. [2, 3] The results were expressed as susceptible, intermediate or resistant according to criteria developed by Clinical Laboratory Standard Institute. [10, 11] Statistical analysis Susceptibility rates were analyzed using ANOVA at significant level of P≤0.05. All interval estimates are 95% confidence intervals. SPSS program for Windows (version 16.0; SPSS, Inc., Chicago, IL) was used. Figure 1 shows the distribution of the clinical isolates of Pseudomonas aeruginosa from the different sites. Ear swab was 23, burns was 30 while wound swabs was 47. From the isolates on wound swabs, no significant difference was recorded in the mean effect of the second generation cephalosporin. On the third generation, Cefpodoxime, Cefixime and Ceftazidime showed significant differences with mean values of 2.96 and 15.67 and 9.94, respectively. Cefepime, a fourth generation, also showed a significant difference with a mean value of 1.17. For Cefotaxime, S is ≥ 23, I is ≤ 15-22 and R is ≤ 14, Cefamandole, S is ≥ 18, I is ≤ 15-17, and R is ≤ 14; for Cefadroxil, S is ≥ 18, I is ≤ 15-17, and R is ≤ 14; for Cefpodoxime, S is ≥ 21, I is ≤ 18-20 and R is ≤17, for Cefador, S is ≥ 18, I is ≤ 15-17 and R is ≤ 14; for Cefexime, S is ≥ 20, I is ≤ 17-19, and R is ≤ 16, for Cefepime, S is ≥ 18, I is ≤ 15-17 and R is ≤ 14. 
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DISCUSSION
Cephalosporin is one of the most widely used antibiotics in the treatment of both grampositive and gram-negative organisms. [2, 3] This study was conducted to evaluate the resistance activity of Pseudomonas aeruginosa obtained from clinical specimens against different generations of cephalosporin. Invitro activities of cephalosporins (Cefamandole, Cefaclor, Cefpodoxime, Cefixime, Ceftazidime and Cefepime) were tested using 100 isolates of Pseudomonas aeruginosa. This bacteria has been reported to develop resistance to antimicrobial agents both through accumulation of resistance genes on extra chromosomal genetic elements as well as through mutational processes. [12, 13, 14, 8] According to previous studies, emerging resistant strains of Pseudomonas aeruginosa are potentially linked to injudicious use of drugs, failure to complete therapeutic regimens and variation in the doses administered leading to ineffective empirical therapy which in turn leads to the appearance of even more resistant strains of the bacterium. [5, 9] Pseudomonas aeruginosa isolates from different sites; wounds (n=47), ear swabs (n=30) and burns (n=23) were found to be similar to those obtained by Masaad [15] and Rajat et al. [16] The majority of the isolates (n = 47) were recovered from infected wounds which agrees with the reports of Masaad, [15] Anuradha et al., [17] Oladipo et al., [2, 5] Eyo et al., [1] Zafer et al., [7] and Shah et al.,. [9] It has been observed that Pseudomonas aeruginosa is more associated with wound infections when compared with other clinical sites.
In this study, Pseudomonas aeruginosa had high resistance to Cefotaxime (99%), Cefamandole (100%) and Cefaclor (100%) which are second generation cephalosporin. This study is comparable with a study by Smith et al., [18] and Tassios et al., [19] with 96% and 92% multidrug resistant isolates respectively. The 99% resistance of Pseudomonas aeruginosa to Cefotaxime does not agree with the reports of Manchi et al., [14] who recorded a resistance of 45% and 55% sensitivity; Anjum et al., [20] who recorded a resistance of 73%, 18% intermediate and 9% sensitivity and Prakash et al., [4] who recorded a resistance of 60.47% this could be as a result of access and usage of antibiotics in this community. However, the intermediate activity against Pseudomonas aeruginosa agrees with the comparative study of Ahmad et al. [21] Also, the resistance (6.0%) and sensitivity (90%) of Pseudomonas aeruginosa to Cefepime in this study does not correlate with the study of Manchi et al., [14] who recorded equal sensitivity and resistance of 50%. This suggests that the organism have developed resistance with the passage of time as explained by Chaudhary and Payasi.
[22] This statement explains the disagreement between this present study and the reports of Manchi et al., [14] and Shah et al., [9] about the resistance of Pseudomonas aeruginosa to Ceftazidime which is 21% to 45% and 45.5% respectively.
In a study conducted by Jazani et al. [23] on antibiotic resistance of Cefepime, it has shown 75.4% resistance, 22.4% intermediate resistance and 2.1% sensitivity. However, in this present study, the observations were comparatively less similar as 6.0% resistance, 4.0% intermediate resistance and 90% sensitivity was seen. This result also disagrees with the reports of Prakash et al. [4] who recorded a resistance of 65.26%, Oladipo et al., [2] who reported a 34.38% sensitivity, 6.25% intermediate and 59.37% resistance as well as Shah et al., [9] who gave a 63.9% resistance. This suggests that the organism have developed resistance with the passage of time as well as inappropriate use of the antibiotics.
Of the tested isolates of Pseudomonas aeruginosa against third generation cephalosporin, Cefpodoxime and Cefixime showed high resistance of 99% and 100% respectively, Ceftazidime showed significant sensitivity with 76%. This result confirmed the findings of Masaad, [15] Kechrid and Hassen, [24] and Ramalingam et al. [8] who found the activity of third generation cephalosporin on Pseudomonas aeruginosa to be 97%. The resistance to second generation cephalosporin could be as a result of drug abuse since they are cheaper as compared to the third and fourth generations. According to Manchi et al., [14] third and fourth generation cephalosporins have better sensitivity when compared to first and second generation as shown from the study carried out in India which agrees with this study. The result also revealed a high sensitivity to Cefepime, a fourth generation, with 90%. This agrees with the result obtained from the studies of Pichichero [25] and Eyo et al., [1] that newer generations of cephalosporin have significant antimicrobial properties than the preceding generations. From the result obtained from this study, Cefepime is considered as empirical therapy of first choice for the treatment of infections caused by Pseudomonas aeruginosa as less resistance was shown.
Analysis from this study showed that a significant difference was observed in the mean effect of fourth generation cephalosporin (Cefepime) on Pseudomonas aeruginosa on the isolates from ear swab, burn and wound, with mean values of 1.26, 1.07 and 1.17 respectively. This may be due to the ability of Pseudomonas aeruginosa obtained from different sites to produce beta-lactamase that reduces the activity of cephalosporin. This result agrees with the report of Pichichero. [25] However, it disagrees with the report of Oladipo et al., [2, 3] with mean effect of the antibiotics on the isolate from ear swab and wound to be 2.32 and 2.45 respectively. No significant difference was observed in the mean effects of both second and third generations cephalosporin used on the clinical isolates of Pseudomonas aeruginosa. This may be due to mutation in the genetic makeup of the bacteria and thus resistance.
CONCLUSION
Antibiotic resistance is threatening the accomplishment of health services and it has since been considered as a universal risk. Third and fourth generation cephalosporins could still be used if found appropriate based on culture and sensitivity despite high incidence of resistance of Pseudomonas aeruginosa to all the different generation of cephalosporins; however, indiscriminate use may lead to increased resistance. Diagnostic procedures should not only aim at identifying the pathogen but also determining its susceptibility to antibiotics before prescription. Furthermore, there should be a continued search for new diagnostic methods due to the complexity of multiresistant phenotypes and emergence of new resistance mechanisms. Also, essential prophylactic measures such as proper hygiene, reducing of the risk factors of nosocomial infections and evidence-based treatment, should be encouraged.
